In-Vitro Maturation of Oocytes From Polycystic Ovarian Patients Undergoing IVF (IVM)

This study has been completed.
Sponsor:
Information provided by:
Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier:
NCT00561808
First received: November 19, 2007
Last updated: March 8, 2010
Last verified: March 2010

November 19, 2007
March 8, 2010
January 2008
Not Provided
Maturation rate of oocytes, their fertilization rate, cleavage rate and embryo quality. [ Time Frame: one year ]
Same as current
Complete list of historical versions of study NCT00561808 on ClinicalTrials.gov Archive Site
Implantation rate and successful delivery. [ Time Frame: one year ]
Same as current
Not Provided
Not Provided
 
In-Vitro Maturation of Oocytes From Polycystic Ovarian Patients Undergoing IVF
In-Vitro Maturation of Oocytes From Polycystic Ovarian Patients Undergoing IVF

Retrieval of immature oocytes from women with polycystic ovaries, their in-vitro maturation, fertilization and embryo transfer can prevent hormonal treatment that can lead to ovarian hyperstimulation. In addition, it can decrease discomfort and side-effects of routine daily administration of hormones and it can be cost-effective. Thirty healthy women with Polycystic Ovarian Syndrome aged 20-35, with BMI 18-30 kg/msq will be included in the study. Their immature oocytes will be retrieved from small follicles without any hormonal treatment. The oocytes will be fertilized post in-vitro maturation. The developed embryros will be transferred to the patients as in a routine IVF cycle.

Not Provided
Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Polycystic Ovarian Syndrome
Other: In-vitro maturation oocytes
Immature oocytes (development stage GV or M1) will be matured in-vitro in IVM culture medium for approximately 28-32 hours. The oocytes will be routinely observed and when they reach maturation (M2) they will be fertilized. The developed embryo will be transferred to the patient 24 hours post-fertilization.
Experimental: Observational
Intervention: Other: In-vitro maturation oocytes
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
30
January 2009
Not Provided

Inclusion Criteria:

  • Healthy women diagnosed with Polycystic Ovarian Syndrome with BMI 18-30 kg/sqm, aged 20-35

Exclusion Criteria:

  • Every one else
Female
20 Years to 35 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Israel
 
NCT00561808
30/2007
Yes
Not Provided
Hillel Yaffe Medical Center
Not Provided
Study Director: Adrian Ellenbogen, MD IVF Unit, Hillel Yaffe Medical Center
Hillel Yaffe Medical Center
March 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP